STOCK TITAN

Endo International plc - $ENDPQ STOCK NEWS

Welcome to our dedicated page for Endo International plc news (Ticker: $ENDPQ), a resource for investors and traders seeking the latest updates and insights on Endo International plc stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Endo International plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Endo International plc's position in the market.

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.29%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.11%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.33%
Tags
Endo International plc

OTC:ENDPQ

ENDPQ Rankings

ENDPQ Stock Data

70.57k
233.69M
0.65%
0.22%
8.47%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
Dublin

About ENDPQ

endo international plc is a global specialty pharmaceutical company focused on improving the lives of patients while creating value. endo develops, manufactures, markets and distributes quality branded and generic pharmaceutical products as well as over-the-counter medications through our operating companies – endo pharmaceuticals, par pharmaceutical, paladin labs, somar and litha. endo commenced operations in 1997 by acquiring certain pharmaceutical products, related rights and assets from the dupont merck pharmaceutical company. since that time, the company has expanded to include the following business segments: u.s. branded pharmaceuticals, u.s. generic pharmaceuticals and international pharmaceuticals. endo’s strategy is to maximize value for our key stakeholders by employing an efficient operating model with focused and disciplined execution that allows us to pursue growth opportunities both organically and through selective acquisitions. additionally, we are leveraging